well, you know i mentioned my late father's still alive, and he talked to me about a thing called taverit's trans cathic aortic valve replacement. >> it was approved in the u.s. ten years ago. this is our tenth anniversary of approval in the u.s. and even though it was revolutionary at the time and there were some spectacular statements made when it was approved, it has improved dramatically over that period of time we've been able to make the system smaller and less invasive there's been less complications, the patients recover faster. there have been remarkable improvements over the years. now these are becoming procedures that happen routinely over 800 hospitals across the u.s. >> now, you were talking about pretty much the whole product line's going to have some very interesting achievements and milestones in 2022 why don't you run through some of those because to me it says that this story is not done. >> oh, no. as a matter of fact, we are just getting started. so, we're going to have nice sales growth, double digit and earnings growth even faster than that in 2022 but what's most